← The SEC Ephemeris: the whole map
Biogen, Inc.
In the graph: all 2 documents (190 pages).
- Application
- NDA 209531
- Ticker
- BIIB
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- September 22, 2025
From FDA letters and SEC filings. Not investment or medical advice.